- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Announcements
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Assemblée générale 2024 de Roche
- Roche Generalversammlung 2024
- Roche Annual General Meeting 2024
More ▼
Key statistics
As of last trade Roche Holding AG (0QQ6:LSE) traded at 235.00, 2.26% above its 52-week low of 229.80, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 247.80 |
Offer | 382.00 |
Previous close | 240.40 |
Average volume | 2.63k |
---|---|
Shares outstanding | 809.25m |
Free float | 731.55m |
P/E (TTM) | 15.43 |
Market cap | 180.93bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.60 CHF |
---|---|
Annual div yield (ADY) | 3.99% |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 20 minutes, as of May 02 2024 14:59 BST.
More ▼